Nektar Therapeutics(Nasdaq:NKTR) will announce its financial results for the third quarter onThursday, November 6, 2025, after the close ofU.S.-based financial markets.Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
https://mma.prnewswire.com/media/1390052/Nektar_Logo_v1.jpg
This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektarwebsite:https://ir.nektar.com/.The web broadcast of the conference call will be available for replay throughDecember 6, 2025.
Toaccesstheconferencecall,pleasepre-registeratNektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.
AboutNektar Therapeutics
Nektar Therapeuticsis a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus.Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered inSan Francisco,California. For further information, visitwww.nektar.comand follow us onLinkedIn.
Contacts:
For Investors:
Vivian WuVWu@nektar.com
Corey Davis, Ph.D.LifeSci Advisors, LLCcdavis@lifesciadvisors.com212-915-2577
Ahu Demir, Ph.D.LifeSci Advisors, LLCademir@lifesciadvisors.com212-915-3820
For Media:
Jonathan PappasLifeSci Communications857-205-4403jpappas@lifescicomms.com
https://edge.prnewswire.com/c/img/favicon.png?sn=SF07715&sd=2025-10-28
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-third-quarter-on-thursday-november-6-2025-after-close-of-us-based-financial-markets-302597142.html
SOURCE Nektar Therapeutics
https://rt.newswire.ca/rt.gif?NewsItemId=SF07715&Transmission_Id=202510281800PR_NEWS_USPR_____SF07715&DateId=20251028